Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTL | Q8NG68 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.40 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31051333 | 0.91 | TTL (0.43) | TTLLMNACYP3A4MEN1TP53 | |
| Scoparic Acid A SCHEMBL31051329 | 0.90 | MAPT (0.42) | TTLLMNACYP3A4MEN1TP53 | |
| Scoparic Acid A SCHEMBL16610421 | 0.90 | MAPT (0.42) | TTLLMNACYP3A4MEN1TP53 | |
| Scoparic Acid A SCHEMBL30621453 | 0.90 | MAPT (0.42) | TTLLMNACYP3A4MEN1TP53 | |
| Scoparic Acid B SCHEMBL14554122 | 0.79 | MAPT (0.43) | TTLLMNACYP3A4MEN1TP53 | |
| Scoparic Acid B SCHEMBL30621452 | 0.79 | MAPT (0.43) | TTLLMNACYP3A4MEN1TP53 | |
| SCHEMBL14552920 | 0.78 | TP53 (0.43) | TTLLMNACYP3A4MEN1TP53 | |
| SCHEMBL16606704 | 0.78 | TP53 (0.43) | TTLLMNACYP3A4MEN1TP53 | |
| Scoparic Acid C SCHEMBL16610413 | 0.76 | MAPT (0.41) | TTLLMNACYP3A4MEN1TP53 | |
| Scoparic Acid C SCHEMBL30621454 | 0.76 | MAPT (0.41) | TTLLMNACYP3A4MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055394-A1 | BARCODED INFLUENZA VIRUSES AND MUTATIONAL SCANNING LIBRARIES INCLUDING THE SAME | FRED HUTCHINSON CANCER CENTER (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250376789-A1 | CELL-STORED BARCODED DEEP MUTATIONAL SCANNING LIBRARIES AND USES OF THE SAME | FRED HUTCHINSON CANCER CENTER (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4652288-A2 | VIRAL PARTICLE PRODUCER CELLS WITH LANDING PAD-INTEGRATED VIRAL VECTORS | Fred Hutchinson Cancer Center (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12421626-B2 | Cell-stored barcoded deep mutational scanning libraries and uses of the same | FRED HUTCHINSON CANCER CENTER (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4569104-A2 | BARCODED INFLUENZA VIRUSES AND MUTATIONAL SCANNING LIBRARIES INCLUDING THE SAME | Fred Hutchinson Cancer Center (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20240299464-A1 | BOTANICAL COMPOUNDS, METHODS, AND PROCEDURES FOR MEDICINAL TREATMENT RELATED TO IMMUNOINFLAMMATION, NEUROINFLAMMATION, DEPRESSION, MEMORY, FOCUS, AND NERVE DEGENERATION | NGUYEN MINH H (US) | 2024-09-12 | — | — | US | disclosed |
| WO-2024173722-A2 | BOTANICAL COMPOUNDS, METHODS, AND PROCEDURES FOR MEDICINAL TREATMENT RELATED TO IMMUNOINFLAMMATION, NEUROINFLAMMATION, DEPRESSION, MEMORY, FOCUS, AND NERVE DEGENERATION | NGUYEN MINH H (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024155830-A2 | VIRAL PARTICLE PRODUCER CELLS WITH LANDING PAD-INTEGRATED VIRAL VECTORS | FRED HUTCHINSON CANCER CENTER (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024036331-A2 | BARCODED INFLUENZA VIRUSES AND MUTATIONAL SCANNING LIBRARIES INCLUDING THE SAME | FRED HUTCHINSON CANCER CENTER (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20240044048-A1 | BARCODED INFLUENZA VIRUSES AND DEEP MUTATIONAL SCANNING LIBRARIES INCLUDING THE SAME | FRED HUTCHINSON CANCER CENTER (US) | 2024-02-08 | — | — | US | disclosed |
| US-11821111-B2 | Barcoded influenza viruses and deep mutational scanning libraries including the same | FRED HUTCHINSON CANCER CENTER (US) | 2023-11-21 | — | — | US | disclosed |
| US-20150093371-A1 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE | Humanitas Technology, LLC (US) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150093371-A1 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE | DDX5, MAVS, EIF2AK2 | TTL 2836/4885LMNA 3080/4885CYP3A4 4301/4885 |
| US-20260055394-A1 | BARCODED INFLUENZA VIRUSES AND MUTATIONAL SCANNING LIBRARIES INCLUDING THE SAME | TRMT1L, UPF1, BPNT1 | TTL 744/4885LMNA 1691/4885CYP3A4 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.